IDWeek - Infectious Disease Week

Islatravir in combination with lenacapavir could become the first weekly oral HIV treatment.

Cabotegravir long-acting when used for HIV pre-exposure prophylaxis (PrEP) showed adherence, effectiveness, and improvements in quality of life by those who received the injection.

Data presented at IDWeek also showed greater disease-prevention effects in the community with PCV21 compared with prior pneumococcal vaccines.

With a new administration protocol created specifically for the routine clinic, infectious disease physicians can treat recurrent clostridioides difficile infection in less than 3 weeks.

Among individuals who received systemic antibiotics within 8 weeks, 6 months, 12 months, and 24 months of receiving fecal microbiota, RBX2660 prevented recurrence.

Health-related quality of life scores were positively associated with log MHI and Bacteriodia, and negatively with Gammaproteobacteria and Bacilli.

Treatment-emergent adverse events associated with Rebyota for Clostridioides difficile infection were more prevalent in those with renal comorbidities than in those without and were moderate in severity as well as related to pre-existing conditions.

Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses being the second pharmacist in IDSA history to receive a society award and what this means not only for her, but for the field.